Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

20073,846 citationsJournal Article

Authors

Malcolm J. Moore · Ontario Institute for Cancer Research

David Goldstein · Ontario Institute for Cancer Research

John Hamm · Ontario Institute for Cancer Research

Arié Figer · Ontario Institute for Cancer Research

J. Randolph Hecht · Ontario Institute for Cancer Research

Steven Gallinger · Ontario Institute for Cancer Research

H. Au

Abstract

To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 25, Issue 15, pp. 1960-1966

DOI: 10.1200/jco.2006.07.9525

Field-Weighted Citation Impact: 119.77